Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Sudafed Sinus Pain Relief 200mg/6.1mg tablets
1001010J0CSABBS
|
Sudafed (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 1 |
|
Sulfinpyrazone 200mg tablets
1001040P0AAACAC
|
Sulfinpyrazone | Sulfinpyrazone | Musculoskeletal and Joint Diseases | 1 |
|
Tocilizumab 400mg/20ml solution for infusion vials
1001030W0AAACAC
|
Tocilizumab | Tocilizumab | Musculoskeletal and Joint Diseases | 1 |
|
Traxam Pain Relief 3% gel
1003020M0BBACAA
|
Traxam | Felbinac | Musculoskeletal and Joint Diseases | 1 |
|
Upadacitinib 30mg modified-release tablets
1001030AEAAABAB
|
Upadacitinib | Upadacitinib | Musculoskeletal and Joint Diseases | 1 |
|
Voltarol Retard 100mg tablets
1001010C0BBAFAF
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 1 |
|
Abatacept 125mg/1ml inj pre-filled syringes
1001030V0AAABAB
|
Abatacept | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Abatacept 250mg powder for solution for infusion vials
1001030V0AAAAAA
|
Abatacept | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Abatacept 50mg/0.4ml inj pre-filled syringes
1001030V0AAAEAE
|
Abatacept | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Abatacept 87.5mg/0.7ml inj pre-filled syringes
1001030V0AAADAD
|
Abatacept | Abatacept | Musculoskeletal and Joint Diseases | No data available |
|
Acadione 250mg tablets
1001030Q0BDAAAB
|
Acadione | Tiopronin | Musculoskeletal and Joint Diseases | No data available |
|
Acemetacin 60mg capsules
100101050AAAAAA
|
Acemetacin | Acemetacin | Musculoskeletal and Joint Diseases | No data available |
|
Acoflam 100mg Retard tablets
1001010C0CDADAF
|
Acoflam | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Acoflam 25mg gastro-resistant tablets
1001010C0CDAAAD
|
Acoflam | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Acoflam 50mg gastro-resistant tablets
1001010C0CDABAE
|
Acoflam | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Acoflam 75mg SR tablets
1001010C0CDACAL
|
Acoflam | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 20mg/0.2ml inj pre-filled syringes
1001030S0AAAFAF
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 20mg/0.4ml inj pre-filled syringes
1001030S0AAAIAI
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 40mg/0.8ml inj pre-filled syringes
1001030S0AAAAAA
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 40mg/0.8ml solution for injection vials
1001030S0AAACAC
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 80mg/0.8ml inj pre-filled disposable devices
1001030S0AAAHAH
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 80mg/0.8ml inj pre-filled syringes
1001030S0AAAGAG
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Advil 200mg tablets
1001010J0CEAAAD
|
Advil | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Advil Extra Strength 400mg tablets
1001010J0CEABAE
|
Advil | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Akis 75mg/1ml solution for injection ampoules
1001010C0CQAABM
|
Akis | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.